Baricitinib is the first drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe stages of alopecia areata in adults.

This medicine, marketed under the name Actonib, is produced by Actoverco pharmaceutical group . Consequently, an event was held with the presence of prominent specialists from various fields to thoroughly review and analyze the effects of this drug.